5 Key Takeaways

• 1

  A 3-year study found that many patients with moderate to severe ulcerative colitis maintained remission with upadacitinib.

• 2

  In the trial, 369 patients who responded to upadacitinib were followed for up to 96 weeks.

• 3

  At week 96, 76% of patients on 15 mg and 74% on 30 mg of upadacitinib were in clinical remission.

• 4

  Endoscopic remission was achieved by nearly half of participants by week 96, with 65% and 73% maintaining it.

• 5

  Safety assessments indicated that serious adverse events were infrequent, with three deaths reported during the study.